Attachment B - Draft Schedule- VANWIHCS Pathology.xlsx
XLSX spreadsheet 172 KB Posted
- Attached to
- VA NWIHCS Pathology Service
- Solicitation number
- 36C26326QXXXX
About this file
This is a draft pricing schedule attachment for a VA pathology and laboratory services contract at the Nebraska-Western Iowa Health Care System (NWIHCS). The schedule provides comprehensive pricing templates for clinical diagnostic laboratory (CLIA) and professional fee schedule services across two contract years (2027-2028), with estimated quantities and unit pricing based on CMS fee schedules.
The pricing structure covers approximately 360 distinct laboratory tests and procedures organized by service category, including molecular pathology, clinical chemistry, hematology, coagulation studies, immunology, microbiology, cytopathology, and surgical pathology. Offerors must populate unit pricing for each CPT/HCPCS code, specify applicable CMS discount rates (with 100% of CMS pricing as the baseline), and identify which laboratory will perform each test using a numerical designation system (0 for self-performed; 1-26 for subcontracted labs). The schedule requires offerors to complete a separate Laboratory Information section documenting all laboratories' names, physical addresses, CLIA numbers, and laboratory director contact information. Key test categories include high-volume procedures such as HPV high-risk pooled testing (972 units annually), tissue examination by pathologist with technical components (1,075 units), cytopath cell enhancement (576 units), and chromosome analysis (92 units), alongside lower-volume specialized tests. The template also accommodates miscellaneous tests with TBD pricing pending methodology determination. All pricing is structured as fixed-price unit costs per test, with total contract pricing calculated by multiplying quantities by unit prices and applicable discount rates.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| Attachment C - RFI Sources Sought _ VANWIHCS Pathology.docx | DOCX document | |
| Attachment A - PWS Draft- Final for NWI Pathology- Updated 7-24-26.docx | DOCX document |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Summary of Lab Information Instructions to Offerors: In order to comply with DC 02.03.01, the laboratory information is required below. Populate the information for any laboratories that will be performing tests under Subcontract. On the subsequent sheets, indicate in column "E" the lab that will be utilized for the test, by the Performing Lab number. If self-performed, please utilize the number "0".
| Performing Lab | Laboratory Name | Laboratory Address (Physical Address not Business Office) | Laboratory CLIA Number | Laboratory Director Name, Email and Phone number |
| 0 | Contractors Lab Information here | Contractors address | Contractors CLIA Number(s) | All POC Information |
| 1 | To Be Provided by Offeror | To Be Provided by Offeror | To Be Provided | To Be Provided |
| 2 | To Be Provided by Offeror | To Be Provided by Offeror | To Be Provided | To Be Provided |
| 3 | To Be Provided by Offeror | To Be Provided by Offeror | To Be Provided | To Be Provided |
| 4 | To Be Provided by Offeror | To Be Provided by Offeror | To Be Provided | To Be Provided |
| 5 | To Be Provided by Offeror | To Be Provided by Offeror | To Be Provided | To Be Provided |
| 6 | To Be Provided by Offeror | To Be Provided by Offeror | To Be Provided | To Be Provided |
| 7 | To Be Provided by Offeror | To Be Provided by Offeror | To Be Provided | To Be Provided |
| 8 | To Be Provided by Offeror | To Be Provided by Offeror | To Be Provided | To Be Provided |
| 9 | To Be Provided by Offeror | To Be Provided by Offeror | To Be Provided | To Be Provided |
| 10 | To Be Provided by Offeror | To Be Provided by Offeror | To Be Provided | To Be Provided |
| 11 | To Be Provided by Offeror | To Be Provided by Offeror | To Be Provided | To Be Provided |
| 12 | To Be Provided by Offeror | To Be Provided by Offeror | To Be Provided | To Be Provided |
| 13 | To Be Provided by Offeror | To Be Provided by Offeror | To Be Provided | To Be Provided |
| 14 | To Be Provided by Offeror | To Be Provided by Offeror | To Be Provided | To Be Provided |
| 15 | To Be Provided by Offeror | To Be Provided by Offeror | To Be Provided | To Be Provided |
| 16 | To Be Provided by Offeror | To Be Provided by Offeror | To Be Provided | To Be Provided |
| 17 | To Be Provided by Offeror | To Be Provided by Offeror | To Be Provided | To Be Provided |
| 18 | To Be Provided by Offeror | To Be Provided by Offeror | To Be Provided | To Be Provided |
| 19 | To Be Provided by Offeror | To Be Provided by Offeror | To Be Provided | To Be Provided |
| 20 | To Be Provided by Offeror | To Be Provided by Offeror | To Be Provided | To Be Provided |
| 21 | To Be Provided by Offeror | To Be Provided by Offeror | To Be Provided | To Be Provided |
| 22 | To Be Provided by Offeror | To Be Provided by Offeror | To Be Provided | To Be Provided |
| 23 | To Be Provided by Offeror | To Be Provided by Offeror | To Be Provided | To Be Provided |
| 24 | To Be Provided by Offeror | To Be Provided by Offeror | To Be Provided | To Be Provided |
| 25 | To Be Provided by Offeror | To Be Provided by Offeror | To Be Provided | To Be Provided |
| 26 | To Be Provided by Offeror | To Be Provided by Offeror | To Be Provided | To Be Provided |
Profee_CMS OP1
| 2027 National Physician Fee Schedule Relative Value |
| CPT codes and descriptions only are copyright 2024 American Medical Association. All Rights Reserved. Applicable FAR Apply. |
| Dental codes (D codes) are copyright 2025/26 American Dental Association. All Rights Reserved. |
| Laboratory Performing Test (Populate corresponding number from Summary of Lab Information, For Self-performed tests, utilize the number '0') | Quantity | UNIT PRICING FOR CONTRACT | CMS Discount Rate (Enter Discount of CMS Amount) | TOTAL CONTRACT PRICING | ||||||
| *KEY | ||||||||||
| 100% of CMS Pricing | ||||||||||
| * | Send Outs | |||||||||
| ** | In-House Special Pricing | |||||||||
| Year | HCPCS / CPT | Send Outs | MOD | DESCRIPTION | ||||||
| Example | 2027 | 12345 | Example: Random Test | 1 | $100.00 | 100.00% | $100.00 | |||
| 0001 | 2027 | 81403 | Mopath procedure level 4 | 24 | $0.00 | |||||
| 0002 | 2027 | 81479 | Unlisted molecular pathology | 28 | $0.00 | |||||
| 0003 | 2027 | 82010 | Ketone bodys quan | 4 | $0.00 | |||||
| 0004 | 2027 | 84220 | Assay of pyruvate kinase | 12 | $0.00 | |||||
| 0005 | 2027 | 85060 | Blood smear interpretation | 5 | $0.00 | |||||
| 0006 | 2027 | 85097 | Bone marrow interpretation | 32 | $0.00 | |||||
| 0007 | 2027 | 86849 | Immunology procedure | 2 | $0.00 | |||||
| 0008 | 2027 | 88040 | Forensic autopsy - Full (necropsy) | 0 | $0.00 | |||||
| 0009 | 2027 | 88099 | Unlisted necropsy (autopsy) | 0 | $0.00 | |||||
| 0010 | 2027 | 88104 | Cytopath fl nongyn smears | 29 | $0.00 | |||||
| 0011 | 2027 | 88104 | TC | Cytopath fl nongyn smears | 0 | $0.00 | ||||
| 0012 | 2027 | 88104 | 26 | Cytopath fl nongyn smears | 0 | $0.00 | ||||
| 0013 | 2027 | 88106 | Cytopath fl nongyn filter | 3 | $0.00 | |||||
| 0014 | 2027 | 88106 | TC | Cytopath fl nongyn filter | 0 | $0.00 | ||||
| 0015 | 2027 | 88108 | Cytopath concentrate tech | 8 | $0.00 | |||||
| 0016 | 2027 | 88108 | TC | Cytopath concentrate tech | 0 | $0.00 | ||||
| 0017 | 2027 | 88112 | Cytopath cell enhance tech | 576 | $0.00 | |||||
| 0018 | 2027 | 88112 | TC | Cytopath cell enhance tech | 0 | $0.00 | ||||
| 0019 | 2027 | 88120 | Cytp urne 3-5 probes ea spec | 8 | $0.00 | |||||
| 0020 | 2027 | 88120 | TC | Cytp urne 3-5 probes ea spec | 0 | $0.00 | ||||
| 0021 | 2027 | 88121 | Cytp urine 3-5 probes cmptr | 8 | $0.00 | |||||
| 0022 | 2027 | 88121 | TC | Cytp urine 3-5 probes cmptr | 0 | $0.00 | ||||
| 0023 | 2027 | 88141 | Cytopath c/v interpret | 13 | $0.00 | |||||
| 0024 | 2027 | 88160 | Cytopath smear other source | 10 | $0.00 | |||||
| 0025 | 2027 | 88160 | TC | Cytopath smear other source | 0 | $0.00 | ||||
| 0026 | 2027 | 88160 | 26 | Cytopath smear other source | 0 | $0.00 | ||||
| 0027 | 2027 | 88161 | Cytopath smear other source | 6 | $0.00 | |||||
| 0028 | 2027 | 88161 | TC | Cytopath smear other source | 0 | $0.00 | ||||
| 0029 | 2027 | 88161 | 26 | Cytopath smear other source | 0 | $0.00 | ||||
| 0030 | 2027 | 88162 | Cytopath smear other source | 6 | $0.00 | |||||
| 0031 | 2027 | 88162 | TC | Cytopath smear other source | 0 | $0.00 | ||||
| 0032 | 2027 | 88162 | 26 | Cytopath smear other source | 0 | $0.00 | ||||
| 0033 | 2027 | 88172 | Cytp dx eval fna 1st ea site | 6 | $0.00 | |||||
| 0034 | 2027 | 88172 | TC | Cytp dx eval fna 1st ea site | 0 | $0.00 | ||||
| 0035 | 2027 | 88173 | Cytopath eval fna report | 49 | $0.00 | |||||
| 0036 | 2027 | 88173 | TC | Cytopath eval fna report | 0 | $0.00 | ||||
| 0037 | 2027 | 88177 | Cytp fna eval ea addl | 9 | $0.00 | |||||
| 0038 | 2027 | 88177 | TC | Cytp fna eval ea addl | 0 | $0.00 | ||||
| 0039 | 2027 | 88177 | 26 | Cytp fna eval ea addl | 0 | $0.00 | ||||
| 0040 | 2027 | 88182 | Cell marker study | 2 | $0.00 | |||||
| 0041 | 2027 | 88182 | TC | Cell marker study | 0 | $0.00 | ||||
| 0042 | 2027 | 88184 | Flowcytometry/ tc 1 marker | 184 | $0.00 | |||||
| 0043 | 2027 | 88185 | Flowcytometry/tc add-on | 31 | $0.00 | |||||
| 0044 | 2027 | 88187 | Flowcytometry/read 2-8 | 33 | $0.00 | |||||
| 0045 | 2027 | 88188 | Flowcytometry/read 9-15 | 35 | $0.00 | |||||
| 0046 | 2027 | 88189 | Flowcytometry/read 16 & > | 60 | $0.00 | |||||
| 0047 | 2027 | 88027 | Necropsy (Autopsy), gross & microscopic with Brain and Spinal Cord | 4 | $0.00 | |||||
| 0048 | 88047 | Autopsy - Electrolyte Panel | 0 | $0.00 | ||||||
| 0049 | 80307 | Autopsy - Comprehensive Drug Panel, Blood | 0 | |||||||
| 0050 | 2027 | 88291 | Cyto/molecular report | 1 | $0.00 | |||||
| 0051 | 2027 | 88300 | Surgical path gross | 0 | $0.00 | |||||
| 0052 | 2027 | 88300 | TC | Surgical path gross | 156 | $0.00 | ||||
| 0053 | 2027 | 88302 | Tissue exam by pathologist | 0 | $0.00 | |||||
| 0054 | 2027 | 88302 | TC | Tissue exam by pathologist | 47 | $0.00 | ||||
| 0055 | 2027 | 88302 | 26 | Tissue exam by pathologist | 0 | $0.00 | ||||
| 0056 | 2027 | 88304 | Tissue exam by pathologist | 0 | $0.00 | |||||
| 0057 | 2027 | 88304 | TC | Tissue exam by pathologist | 266 | $0.00 | ||||
| 0058 | 2027 | 88304 | 26 | Tissue exam by pathologist | 0 | $0.00 | ||||
| 0059 | 2027 | 88305 | Tissue exam by pathologist | 0 | $0.00 | |||||
| 0060 | 2027 | 88305 | TC | Tissue exam by pathologist | 1075 | $0.00 | ||||
| 0061 | 2027 | 88305 | 26 | Tissue exam by pathologist | 0 | $0.00 | ||||
| 0062 | 2027 | 88307 | Tissue exam by pathologist | 0 | $0.00 | |||||
| 0063 | 2027 | 88307 | TC | Tissue exam by pathologist | 494 | $0.00 | ||||
| 0064 | 2027 | 88307 | 26 | Tissue exam by pathologist | 0 | $0.00 | ||||
| 0065 | 2027 | 88309 | Tissue exam by pathologist | 0 | $0.00 | |||||
| 0066 | 2027 | 88309 | TC | Tissue exam by pathologist | 141 | $0.00 | ||||
| 0067 | 2027 | 88309 | 26 | Tissue exam by pathologist | 0 | $0.00 | ||||
| 0068 | 2027 | 88311 | Decalcify tissue | 0 | $0.00 | |||||
| 0069 | 2027 | 88311 | TC | Decalcify tissue | 58 | $0.00 | ||||
| 0070 | 2027 | 88312 | Special stains group 1 | 0 | $0.00 | |||||
| 0071 | 2027 | 88312 | TC | Special stains group 1 | 308 | $0.00 | ||||
| 0072 | 2027 | 88313 | Special stains group 2 | 0 | $0.00 | |||||
| 0073 | 2027 | 88313 | TC | Special stains group 2 | 222 | $0.00 | ||||
| 0074 | 2027 | 88313 | 26 | Special stains group 2 | 0 | $0.00 | ||||
| 0075 | 2027 | 88314 | Histochemical stains add-on | 13 | $0.00 | |||||
| 0076 | 2027 | 88314 | TC | Histochemical stains add-on | 24 | $0.00 | ||||
| 0077 | 2027 | 88319 | Enzyme histochemistry | 9 | $0.00 | |||||
| 0078 | 2027 | 88319 | TC | Enzyme histochemistry | 5 | $0.00 | ||||
| 0079 | 2027 | 88321 | Consltj&reprt sld prep elswr | 56 | $0.00 | |||||
| 0080 | 2027 | 88323 | Consltj&reprt matrl prep sld | 29 | $0.00 | |||||
| 0081 | 2027 | 88341 | Imhchem/imcytchm ea add antb | 0 | $0.00 | |||||
| 0082 | 2027 | 88341 | TC | Imhchem/imcytchm ea add antb | 266 | $0.00 | ||||
| 0083 | 2027 | 88341 | 26 | Imhchem/imcytchm ea add antb | 0 | $0.00 | ||||
| 0084 | 2027 | 88342 | Imhchem/imcytchm 1st antb | 0 | $0.00 | |||||
| 0085 | 2027 | 88342 | TC | Imhchem/imcytchm 1st antb | 202 | $0.00 | ||||
| 0086 | 2027 | 88342 | 26 | Imhchem/imcytchm 1st antb | 0 | $0.00 | ||||
| 0087 | 2027 | 88344 | Imhchem/imcytchm ea mlt antb | 0 | $0.00 | |||||
| 0088 | 2027 | 88344 | TC | Imhchem/imcytchm ea mlt antb | 119 | $0.00 | ||||
| 0089 | 2027 | 88346 | Imfluor 1st 1antb stain px | 0 | $0.00 | |||||
| 0090 | 2027 | 88346 | TC | Imfluor 1st 1antb stain px | 79 | $0.00 | ||||
| 0091 | 2027 | 88348 | Electron microscopy dx | 12 | $0.00 | |||||
| 0092 | 2027 | 88348 | TC | Electron microscopy dx | 9 | $0.00 | ||||
| 0093 | 2027 | 88350 | Imfluor ea addl 1antb stn px | 55 | $0.00 | |||||
| 0094 | 2027 | 88350 | TC | Imfluor ea addl 1antb stn px | 21 | $0.00 | ||||
| 0095 | 2027 | 88360 | Tumor immunohistochem/manual | 24 | $0.00 | |||||
| 0096 | 2027 | 88360 | TC | Tumor immunohistochem/manual | 32 | $0.00 | ||||
| 0097 | 2027 | 88361 | TC | Tumor immunohistochem/comput | 1 | $0.00 | ||||
| 0098 | 2027 | 88364 | Insitu hybridization (fish) | 17 | $0.00 | |||||
| 0099 | 2027 | 88364 | TC | Insitu hybridization (fish) | 23 | $0.00 | ||||
| 0100 | 2027 | 88365 | Insitu hybridization (fish) | 29 | $0.00 | |||||
| 0101 | 2027 | 88365 | TC | Insitu hybridization (fish) | 32 | $0.00 | ||||
| 0102 | 2027 | 88367 | TC | Insitu hybridization auto | 1 | $0.00 | ||||
| 0103 | 2027 | 88368 | TC | Insitu hybridization manual | 9 | $0.00 | ||||
| 0104 | 2027 | 88374 | M/phmtrc alys ishquant/semiq | 28 | $0.00 | |||||
| 0105 | 2027 | 88377 | M/phmtrc alys ishquant/semiq | 34 | $0.00 | |||||
| 0106 | 2027 | 88377 | TC | M/phmtrc alys ishquant/semiq | 7 | $0.00 | ||||
| 0107 | 2027 | 88381 | Microdissection manual | 16 | $0.00 | |||||
| 0108 | 2027 | 88381 | TC | Microdissection manual | 9 | $0.00 | ||||
| 0109 | 2027 | 88399 | Unlisted surgical path px | 3 | $0.00 | |||||
| 0110 | 2027 | 89240 | Unlisted misc path test | 33 | $0.00 | |||||
| 0111 | 2027 | 99001 | Specimen handling pt-lab | 2 | $0.00 | |||||
| 0112 | 2027 | TBD | Miscellaneous test varies depending on methodology/pathways | 0 | TBD | ERROR:#VALUE! | ||||
| $0.00 |
$0.00
CLIA OP1
| 2027 Clinical Diagnostic Laboratory Fee Schedule | |||||||||||||
| CPT codes, descriptions and other data only are copyright 2025 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. | |||||||||||||
| *KEY | |||||||||||||
| 100% of CMS Pricing | |||||||||||||
| * | Send Outs | ||||||||||||
| ** | In-House Special Pricing | ||||||||||||
| LIN | YEAR | HCSPCS / CPT | Send Outs | MOD | Short Description | Extended Description | Laboratory Performing Test (Populate corresponding number from Summary of Lab Information, For Self-performed tests, utilize the number '0') | CMS INDICATOR | Quantity | UNIT PRICING FOR CONTRACT | CMS Discount Rate (Enter Discount of CMS Amount) | TOTAL - CONTRACT PRICING | |
| Example | 2027 | 12345 | Example: Random Test | 5 | $100.00 | 100.00% | $500.00 | 100.00% | |||||
| 0113 | 2027 | 0012M | Onc mrna 5 gen rsk urthl ca | Oncology (urothelial), mrna, gene expression profiling by real-time quantitative pcr of five genes (mdk, hoxa13, cdc2 [cdk1], igfbp5, and cxcr2), utilizing urine, algorithm reported as a risk score for having urothelial carcinoma | N | 1 | $0.00 | ||||||
| 0114 | 2027 | 0013M | Onc mrna 5 gen recr urthl ca | Oncology (urothelial), mrna, gene expression profiling by real-time quantitative pcr of five genes (mdk, hoxa13, cdc2 [cdk1], igfbp5, and cxcr2), utilizing urine, algorithm reported as a risk score for having recurrent urothelial carcinoma | N | 1 | $0.00 | ||||||
| 0115 | 2027 | 0035U | Neuro csf prion prtn qual | Neurology (prion disease), cerebrospinal fluid, detection of prion protein by quaking-induced conformational conversion, qualitative | N | 1 | $0.00 | ||||||
| 0116 | 2027 | 80047 | Metabolic panel ionized ca | Basic metabolic panel (calcium, ionized) this panel must include the following: calcium, ionized (82330) carbon dioxide (bicarbonate) (82374) chloride (82435) creatinine (82565) glucose (82947) potassium (84132) sodium (84295) urea nitrogen (bun) (84520) | N | 1 | $0.00 | ||||||
| 0117 | 2027 | 80048 | Metabolic panel total ca | Basic metabolic panel (calcium, total) this panel must include the following: calcium, total (82310) carbon dioxide (bicarbonate) (82374) chloride (82435) creatinine (82565) glucose (82947) potassium (84132) sodium (84295) urea nitrogen (bun) (84520) | N | 4 | $0.00 | ||||||
| 0118 | 2027 | 80053 | Comprehen metabolic panel | Comprehensive metabolic panel this panel must include the following: albumin (82040) bilirubin, total (82247) calcium, total (82310) carbon dioxide (bicarbonate) (82374) chloride (82435) creatinine (82565) glucose (82947) phosphatase, alkaline (84075) potassium (84132) protein, total (84155) sodium (84295) transferase, alanine amino (alt) (sgpt) (84460) transferase, aspartate amino (ast) (sgot) (84450) urea nitrogen (bun) (84520) | N | 13 | $0.00 | ||||||
| 0119 | 2027 | 80061 | Lipid panel | Lipid panel this panel must include the following: cholesterol, serum, total (82465) lipoprotein, direct measurement, high density cholesterol (hdl cholesterol) (83718) triglycerides (84478) | N | 1 | $0.00 | ||||||
| 0120 | 2027 | 80150 | Assay of amikacin | Amikacin | N | 1 | $0.00 | ||||||
| 0121 | 2027 | 80156 | Assay carbamazepine total | Carbamazepine; total | N | 1 | $0.00 | ||||||
| 0122 | 2027 | 80170 | Assay of gentamicin | Gentamicin | N | 1 | $0.00 | ||||||
| 0123 | 2027 | 80185 | Assay of phenytoin total | Phenytoin; total | N | 1 | $0.00 | ||||||
| 0124 | 2027 | 80186 | Assay of phenytoin free | Phenytoin; free | N | 1 | $0.00 | ||||||
| 0125 | 2027 | 80194 | Assay of quinidine | Quinidine | N | 1 | $0.00 | ||||||
| 0126 | 2027 | 80197 | Assay of tacrolimus | Tacrolimus | N | 1 | $0.00 | ||||||
| 0127 | 2027 | 80202 | Assay of vancomycin | Vancomycin | N | 5 | $0.00 | ||||||
| 0128 | 2027 | 80204 | Drug assay methotrexate | Methotrexate | N | 3 | $0.00 | ||||||
| 0129 | 2027 | 80299 | Quantitative assay drug | Quantitation of therapeutic drug, not elsewhere specified | N | 73 | $0.00 | ||||||
| 0130 | 2027 | 80305 | Drug test prsmv dir opt obs | Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; capable of being read by direct optical observation only (eg, utilizing immunoassay [eg, dipsticks, cups, cards, or cartridges]), includes sample validation when performed, per date of service | N | 1 | $0.00 | ||||||
| 0131 | 2027 | 80306 | Drug test prsmv instrmnt | Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; read by instrument assisted direct optical observation (eg, utilizing immunoassay [eg, dipsticks, cups, cards, or cartridges]), includes sample validation when performed, per date of service | N | 1 | $0.00 | ||||||
| 0132 | 2027 | 80307 | Drug test prsmv chem anlyzr | Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; by instrument chemistry analyzers (eg, utilizing immunoassay [eg, eia, elisa, emit, fpia, ia, kims, ria]), chromatography (eg, gc, hplc), and mass spectrometry either with or without chromatography, (eg, dart, desi, gc-ms, gc-ms/ms, lc-ms, lc-ms/ms, ldtd, maldi, tof) includes sample validation when performed, per date of service | N | 2 | $0.00 | ||||||
| 0133 | 2027 | 81120 | Idh1 common variants | Idh1 (isocitrate dehydrogenase 1 [nadp+], soluble) (eg, glioma), common variants (eg, r132h, r132c) | N | 16 | $0.00 | ||||||
| 0134 | 2027 | 81121 | Idh2 common variants | Idh2 (isocitrate dehydrogenase 2 [nadp+], mitochondrial) (eg, glioma), common variants (eg, r140w, r172m) | N | 15 | $0.00 | ||||||
| 0135 | 2027 | 81170 | Abl1 gene | Abl1 (abl proto-oncogene 1, non-receptor tyrosine kinase) (eg, acquired imatinib tyrosine kinase inhibitor resistance), gene analysis, variants in the kinase domain | N | 5 | $0.00 | ||||||
| 0136 | 2027 | 81206 | Bcr/abl1 gene major bp | Bcr/abl1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis; major breakpoint, qualitative or quantitative | N | 40 | $0.00 | ||||||
| 0137 | 2027 | 81207 | Bcr/abl1 gene minor bp | Bcr/abl1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis; minor breakpoint, qualitative or quantitative | N | 9 | $0.00 | ||||||
| 0138 | 2027 | 81210 | Braf gene | Braf (b-raf proto-oncogene, serine/threonine kinase) (eg, colon cancer, melanoma), gene analysis, v600 variant(s) | N | 5 | $0.00 | ||||||
| 0139 | 2027 | 81219 | Calr gene com variants | Calr (calreticulin) (eg, myeloproliferative disorders), gene analysis, common variants in exon 9 | N | 11 | $0.00 | ||||||
| 0140 | 2027 | 81245 | Flt3 gene | Flt3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia), gene analysis; internal tandem duplication (itd) variants (ie, exons 14, 15) | N | 68 | $0.00 | ||||||
| 0141 | 2027 | 81246 | Flt3 gene analysis | Flt3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia), gene analysis; tyrosine kinase domain (tkd) variants (eg, d835, i836) | N | 7 | $0.00 | ||||||
| 0142 | 2027 | 81261 | Igh gene rearrange amp meth | Igh@ (immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, b-cell), gene rearrangement analysis to detect abnormal clonal population(s); amplified methodology (eg, polymerase chain reaction) | N | 12 | $0.00 | ||||||
| 0143 | 2027 | 81270 | Jak2 gene | Jak2 (janus kinase 2) (eg, myeloproliferative disorder) gene analysis, p.val617phe (v617f) variant | N | 244 | $0.00 | ||||||
| 0144 | 2027 | 81272 | Kit gene targeted seq analys | Kit (v-kit hardy-zuckerman 4 feline sarcoma viral oncogene homolog) (eg, gastrointestinal stromal tumor [gist], acute myeloid leukemia, melanoma), gene analysis, targeted sequence analysis (eg, exons 8, 11, 13, 17, 18) | N | 8 | $0.00 | ||||||
| 0145 | 2027 | 81275 | Kras gene variants exon 2 | Kras (kirsten rat sarcoma viral oncogene homolog) (eg, carcinoma) gene analysis; variants in exon 2 (eg, codons 12 and 13) | N | 22 | $0.00 | ||||||
| 0146 | 2027 | 81276 | Kras gene addl variants | Kras (kirsten rat sarcoma viral oncogene homolog) (eg, carcinoma) gene analysis; additional variant(s) (eg, codon 61, codon 146) | N | 5 | $0.00 | ||||||
| 0147 | 2027 | 81301 | Microsatellite instability | Microsatellite instability analysis (eg, hereditary non-polyposis colorectal cancer, lynch syndrome) of markers for mismatch repair deficiency (eg, bat25, bat26), includes comparison of neoplastic and normal tissue, if performed | N | 5 | $0.00 | ||||||
| 0148 | 2027 | 81305 | Myd88 gene p.leu265pro vrnt | Myd88 (myeloid differentiation primary response 88) (eg, waldenstrom's macroglobulinemia, lymphoplasmacytic leukemia) gene analysis, p.leu265pro (l265p) variant | N | 10 | $0.00 | ||||||
| 0149 | 2027 | 81310 | Npm1 gene | Npm1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, exon 12 variants | N | 40 | $0.00 | ||||||
| 0150 | 2027 | 81311 | Nras gene variants exon 2&3 | Nras (neuroblastoma ras viral [v-ras] oncogene homolog) (eg, colorectal carcinoma), gene analysis, variants in exon 2 (eg, codons 12 and 13) and exon 3 (eg, codon 61) | N | 5 | $0.00 | ||||||
| 0151 | 2027 | 81314 | Pdgfra gene | Pdgfra (platelet-derived growth factor receptor, alpha polypeptide) (eg, gastrointestinal stromal tumor [gist]), gene analysis, targeted sequence analysis (eg, exons 12, 18) | N | 12 | $0.00 | ||||||
| 0152 | 2027 | 81315 | Pml/raralpha com breakpoints | Pml/raralpha, (t(15;17)), (promyelocytic leukemia/retinoic acid receptor alpha) (eg, promyelocytic leukemia) translocation analysis; common breakpoints (eg, intron 3 and intron 6), qualitative or quantitative | N | 4 | $0.00 | ||||||
| 0153 | 2027 | 81342 | Trg gene rearrangement anal | Trg@ (t cell antigen receptor, gamma) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population(s) | N | 76 | $0.00 | ||||||
| 0154 | 2027 | 81345 | Tert gene targeted seq alys | Tert (telomerase reverse transcriptase) (eg, thyroid carcinoma, glioblastoma multiforme) gene analysis, targeted sequence analysis (eg, promoter region) | N | 1 | $0.00 | ||||||
| 0155 | 2027 | 81401 | Mopath procedure level 2 | Molecular pathology procedure, level 2 (eg, 2-10 snps, 1 methylated variant, or 1 somatic variant [typically using nonsequencing target variant analysis], or detection of a dynamic mutation disorder/triplet repeat) abcc8 (atp-binding cassette, sub-family c [cftr/mrp], member 8) (eg, familial hyperinsulinism), common variants (eg, c.3898-9g>a [c.3992-9g>a], f1388del) abl1 (abl proto-oncogene 1, non-receptor tyrosine kinase) (eg, acquired imatinib resistance), t315i variant acadm (acyl-coa dehydrogenase, c-4 to c-12 straight chain, mcad) (eg, medium chain acyl dehydrogenase deficiency), commons variants (eg, k304e, y42h) adrb2 (adrenergic beta-2 receptor surface) (eg, drug metabolism), common variants (eg, g16r, q27e) apob (apolipoprotein b) (eg, familial hypercholesterolemia type b), common variants (eg, r3500q, r3500w) apoe (apolipoprotein e) (eg, hyperlipoproteinemia type iii, cardiovascular disease, alzheimer disease), common variants (eg, *2, *3, *4) cbfb/myh11 (inv(16)) (eg, acute myeloid leukemia), qualitative, and quantitative, if performed cbs (cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), common variants (eg, i278t, g307s) cfh/arms2 (complement factor h/age-related maculopathy susceptibility 2) (eg, macular degeneration), common variants (eg, y402h [cfh], a69s [arms2]) dek/nup214 (t(6;9)) (eg, acute myeloid leukemia), translocation analysis, qualitative, and quantitative, if performed e2a/pbx1 (t(1;19)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed eml4/alk (inv(2)) (eg, non-small cell lung cancer), translocation or inversion analysis etv6/runx1 (t(12;21)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed ewsr1/atf1 (t(12;22)) (eg, clear cell sarcoma), translocation analysis, qualitative, and quantitative, if performed ewsr1/erg (t(21;22)) (eg, ewing sarcoma/peripheral neuroectodermal tumor), translocation analysis, qualitative, and quantitative, if performed ewsr1/fli1 (t(11;22)) (eg, ewing sarcoma/peripheral neuroectodermal tumor), translocation analysis, qualitative, and quantitative, if performed ewsr1/wt1 (t(11;22)) (eg, desmoplastic small round cell tumor), translocation analysis, qualitative, and quantitative, if performed f11 (coagulation factor xi) (eg, coagulation disorder), common variants (eg, e117x [type ii], f283l [type iii], ivs14del14, and ivs14+1g>a [type i]) fgfr3 (fibroblast growth factor receptor 3) (eg, achondroplasia, hypochondroplasia), common variants (eg, 1138g>a, 1138g>c, 1620c>a, 1620c>g) fip1l1/pdgfra (del[4q12]) (eg, imatinib-sensitive chronic eosinophilic leukemia), qualitative, and quantitative, if performed flg (filaggrin) (eg, ichthyosis vulgaris), common variants (eg, r501x, 2282del4, r2447x, s3247x, 3702delg) foxo1/pax3 (t(2;13)) (eg, alveolar rhabdomyosarcoma), translocation analysis, qualitative, and quantitative, if performed foxo1/pax7 (t(1;13)) (eg, alveolar rhabdomyosarcoma), translocation analysis, qualitative, and quantitative, if performed fus/ddit3 (t(12;16)) (eg, myxoid liposarcoma), translocation analysis, qualitative, and quantitative, if performed galc (galactosylceramidase) (eg, krabbe disease), common variants (eg, c.857g>a, 30-kb deletion) galt (galactose-1-phosphate uridylyltransferase) (eg, galactosemia), common variants (eg, q188r, s135l, k285n, t138m, l195p, y209c, ivs2-2a>g, p171s, del5kb, n314d, l218l/n314d) h19 (imprinted maternally expressed transcript [non-protein coding]) (eg, beckwith-wiedemann syndrome), methylation analysis igh@/bcl2 (t(14;18)) (eg, follicular lymphoma), translocation analysis; single breakpoint (eg, major breakpoint region [mbr] or minor cluster region [mcr]), qualitative or quantitative (when both mbr and mcr breakpoints are performed, use 81278) kcnq1ot1 (kcnq1 overlapping transcript 1 [non-protein coding]) (eg, beckwith-wiedemann syndrome), methylation analysis linc00518 (long intergenic non-protein coding rna 518) (eg, melanoma), expression analysis lrrk2 (leucine-rich repeat kinase 2) (eg, parkinson disease), common variants (eg, r1441g, g2019s, i2020t) med12 (mediator complex subunit 12) (eg, fg syndrome type 1, lujan syndrome), common variants (eg, r961w, n1007s) meg3/dlk1 (maternally expressed 3 [non-protein coding]/delta-like 1 homolog [drosophila]) (eg, intrauterine growth retardation), methylation analysis mll/aff1 (t(4;11)) (eg, acute lymphoblastic leukemia), translocation analysis, qualitative, and quantitative, if performed mll/mllt3 (t(9;11)) (eg, acute myeloid leukemia), translocation analysis, qualitative, and quantitative, if performed mt-atp6 (mitochondrially encoded atp synthase 6) (eg, neuropathy with ataxia and retinitis pigmentosa [narp], coli]) (eg, myh-associated polyposis), common variants (eg, y165c, g382d) nod2 (nucleotide-binding oligomerization domain containing 2) (eg, crohn's disease, blau syndrome), common variants (eg, snp 8, snp 12, snp 13) npm1/alk (t(2;5)) (eg, anaplastic large cell lymphoma), translocation analysis pax8/pparg (t(2;3) (q13;p25)) (eg, follicular thyroid carcinoma), translocation analysis prame (preferentially expressed antigen in melanoma) (eg, melanoma), expression analysis prss1 (protease, serine, 1 [trypsin 1]) (eg, hereditary pancreatitis), common variants (eg, n29i, a16v, r122h) pygm (phosphorylase, glycogen, muscle) (eg, glycogen storage disease type v, mcardle disease), common variants (eg, r50x, g205s) runx1/runx1t1 (t(8;21)) (eg, acute myeloid leukemia) translocation analysis, qualitative, and quantitative, if performed ss18/ssx1 (t(x;18)) (eg, synovial sarcoma), translocation analysis, qualitative, and quantitative, if performed ss18/ssx2 (t(x;18)) (eg, synovial sarcoma), translocation analysis, qualitative, and quantitative, if performed vwf (von willebrand factor) (eg, von willebrand disease type 2n), common variants (eg, t791m, r816w, r854q) | N | 7 | $0.00 | ||||||
| 0156 | 2027 | 81403 | Mopath procedure level 4 | Molecular pathology procedure, level 4 (eg, analysis of single exon by dna sequence analysis, analysis of >10 amplicons using multiplex pcr in 2 or more independent reactions, mutation scanning or duplication/deletion variants of 2-5 exons) ang (angiogenin, ribonuclease, rnase a family, 5) (eg, amyotrophic lateral sclerosis), full gene sequence arx (aristaless related homeobox) (eg, x-linked lissencephaly with ambiguous genitalia, x-linked intellectual disability), duplication/deletion analysis cel (carboxyl ester lipase [bile salt-stimulated lipase]) (eg, maturity-onset diabetes of the young [mody]), targeted sequence analysis of exon 11 (eg, c.1785delc, c.1686delt) ctnnb1 (catenin [cadherin-associated protein], beta 1, 88kda) (eg, desmoid tumors), targeted sequence analysis (eg, exon 3) daz/sry (deleted in azoospermia and sex determining region y) (eg, male infertility), common deletions (eg, azfa, azfb, azfc, azfd) dnmt3a (dna [cytosine-5-]-methyltransferase 3 alpha) (eg, acute myeloid leukemia), targeted sequence analysis (eg, exon 23) epcam (epithelial cell adhesion molecule) (eg, lynch syndrome), duplication/deletion analysis f8 (coagulation factor viii) (eg, hemophilia a), inversion analysis, intron 1 and intron 22a f12 (coagulation factor xii [hageman factor]) (eg, angioedema, hereditary, type iii; factor xii deficiency), targeted sequence analysis of exon 9 fgfr3 (fibroblast growth factor receptor 3) (eg, isolated craniosynostosis), targeted sequence analysis (eg, exon 7) (for targeted sequence analysis of multiple fgfr3 exons, use 81404) gjb1 (gap junction protein, beta 1) (eg, charcot-marie-tooth x-linked), full gene sequence gnaq (guanine nucleotide-binding protein g[q] subunit alpha) (eg, uveal melanoma), common variants (eg, r183, q209) human erythrocyte antigen gene analyses (eg, slc14a1 [kidd blood group], bcam [lutheran blood group], icam4 [landsteiner-wiener blood group], slc4a1 [diego blood group], aqp1 [colton blood group], ermap [scianna blood group], rhce [rh blood group, ccee antigens], kel [kell blood group], darc [duffy blood group], gypa, gypb, gype [mns blood group], art4 [dombrock blood group]) (eg, sickle-cell disease, thalassemia, hemolytic transfusion reactions, hemolytic disease of the fetus or newborn), common variants hras (v-ha-ras harvey rat sarcoma viral oncogene homolog) (eg, costello syndrome), exon 2 sequence kcnc3 (potassium voltage-gated channel, shaw-related subfamily, member 3) (eg, spinocerebellar ataxia), targeted sequence analysis (eg, exon 2) kcnj2 (potassium inwardly-rectifying channel, subfamily j, member 2) (eg, andersen-tawil syndrome), full gene sequence kcnj11 (potassium inwardly-rectifying channel, subfamily j, member 11) (eg, familial hyperinsulinism), full gene sequence killer cell immunoglobulin-like receptor (kir) gene family (eg, hematopoietic stem cell transplantation), genotyping of kir family genes known familial variant not otherwise specified, for gene listed in tier 1 or tier 2, or identified during a genomic sequencing procedure, dna sequence analysis, each variant exon (for a known familial variant that is considered a common variant, use specific common variant tier 1 or tier 2 code) mc4r (melanocortin 4 receptor) (eg, obesity), full gene sequence mica (mhc class i polypeptide-related sequence a) (eg, solid organ transplantation), common variants (eg, *001, *002) mt-rnr1 (mitochondrially encoded 12s rna) (eg, nonsyndromic hearing loss), full gene sequence mt-ts1 (mitochondrially encoded trna serine 1) (eg, nonsyndromic hearing loss), full gene sequence ndp (norrie disease [pseudoglioma]) (eg, norrie disease), duplication/deletion analysis nhlrc1 (nhl repeat containing 1) (eg, progressive myoclonus epilepsy), full gene sequence phox2b (paired-like homeobox 2b) (eg, congenital central hypoventilation syndrome), duplication/deletion analysis pln (phospholamban) (eg, dilated cardiomyopathy, hypertrophic cardiomyopathy), full gene sequence rhd (rh blood group, d antigen) (eg, hemolytic disease of the fetus and newborn, rh maternal/fetal compatibility), deletion analysis (eg, exons 4, 5, and 7, pseudogene) rhd (rh blood group, d antigen) (eg, hemolytic disease of the fetus and newborn, rh maternal/fetal compatibility), deletion analysis (eg, exons 4, 5, and 7, pseudogene), performed on cell-free fetal dna in maternal blood (for human erythrocyte gene analysis of rhd, use a separate unit of 81403) sh2d1a (sh2 domain containing 1a) (eg, x-linked lymphoproliferative syndrome), duplication/deletion analysis twist1 (twist homolog 1 [drosophila]) (eg, saethre-chotzen syndrome), duplication/deletion analysis uba1 (ubiquitin-like modifier activating enzyme 1) (eg, spinal muscular atrophy, x-linked), targeted sequence analysis (eg, exon 15) vhl (von hippel-lindau tumor suppressor) (eg, von hippel-lindau familial cancer syndrome), deletion/duplication analysis vwf (von willebrand factor) (eg, von willebrand disease types 2a, 2b, 2m), targeted sequence analysis (eg, exon 28) | N | 104 | $0.00 | ||||||
| 0157 | 2027 | 81425 | Genome sequence analysis | Genome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis | N | 1 | $0.00 | ||||||
| 0158 | 2027 | 81445 | So neo gsap 5-50dna/dna&rna | Solid organ neoplasm, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants and copy number variants or rearrangements, if performed; dna analysis or combined dna and rna analysis | N | 9 | $0.00 | ||||||
| 0159 | 2027 | 81450 | Hl neo gsap 5-50dna/dna&rna | Hematolymphoid neoplasm or disorder, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants, and copy number variants or rearrangements, or isoform expression or mrna expression levels, if performed; dna analysis or combined dna and rna analysis | N | 5 | $0.00 | ||||||
| 0160 | 2027 | 81546 | Onc thyr mrna 10,196 gen alg | Oncology (thyroid), mrna, gene expression analysis of 10,196 genes, utilizing fine needle aspirate, algorithm reported as a categorical result (eg, benign or suspicious) | N | 12 | $0.00 | ||||||
| 0161 | 2027 | 82010 | Ketone bodys quan | Ketone body(s) (eg, acetone, acetoacetic acid, beta-hydroxybutyrate); quantitative | N | 7 | $0.00 | ||||||
| 0162 | 2027 | 82043 | Ur albumin quantitative | Albumin; urine (eg, microalbumin), quantitative | N | 8 | $0.00 | ||||||
| 0163 | 2027 | 82105 | Alpha-fetoprotein serum | Alpha-fetoprotein (afp); serum | N | 4 | $0.00 | ||||||
| 0164 | 2027 | 82172 | Assay of apolipoprotein | Apolipoprotein, each | N | 1 | $0.00 | ||||||
| 0165 | 2027 | 82175 | Assay of arsenic | Arsenic | N | 1 | $0.00 | ||||||
| 0166 | 2027 | 82261 | Assay of biotinidase | Biotinidase, each specimen | N | 25 | $0.00 | ||||||
| 0167 | 2027 | 82271 | Occult blood other sources | Blood, occult, by peroxidase activity (eg, guaiac), qualitative; other sources | N | 16 | $0.00 | ||||||
| 0168 | 2027 | 82330 | Assay of calcium | Calcium; ionized | N | 5 | $0.00 | ||||||
| 0169 | 2027 | 82365 | Calculus spectroscopy | Calculus; infrared spectroscopy | N | 432 | $0.00 | ||||||
| 0170 | 2027 | 82533 | Total cortisol | Cortisol; total | N | 1 | $0.00 | ||||||
| 0171 | 2027 | 82542 | Col chromotography qual/quan | Column chromatography, includes mass spectrometry, if performed (eg, hplc, lc, lc/ms, lc/ms-ms, gc, gc/ms-ms, gc/ms, hplc/ms), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen | N | 60 | $0.00 | ||||||
| 0172 | 2027 | 82550 | Assay of ck (cpk) | Creatine kinase (ck), (cpk); total | N | 1 | $0.00 | ||||||
| 0173 | 2027 | 82552 | Assay of cpk in blood | Creatine kinase (ck), (cpk); isoenzymes | N | 1 | $0.00 | ||||||
| 0174 | 2027 | 82553 | Creatine mb fraction | Creatine kinase (ck), (cpk); mb fraction only | N | 1 | $0.00 | ||||||
| 0175 | 2027 | 82565 | Assay of creatinine | Creatinine; blood | N | 20 | $0.00 | ||||||
| 0176 | 2027 | 82585 | Assay of cryofibrinogen | Cryofibrinogen | N | 9 | $0.00 | ||||||
| 0177 | 2027 | 82595 | Assay of cryoglobulin | Cryoglobulin, qualitative or semi-quantitative (eg, cryocrit) | N | 7 | $0.00 | ||||||
| 0178 | 2027 | 82607 | Vitamin b-12 | Cyanocobalamin (vitamin b-12); | N | 4 | $0.00 | ||||||
| 0179 | 2027 | 82693 | Assay of ethylene glycol | Ethylene glycol | N | 5 | $0.00 | ||||||
| 0180 | 2027 | 82705 | Fats/lipids feces qual | Fat or lipids, feces; qualitative | N | 21 | $0.00 | ||||||
| 0181 | 2027 | 82728 | Assay of ferritin | Ferritin | N | 3 | $0.00 | ||||||
| 0182 | 2027 | 82746 | Assay of folic acid serum | Folic acid; serum | N | 5 | $0.00 | ||||||
| 0183 | 2027 | 82784 | Assay iga/igd/igg/igm each | Gammaglobulin (immunoglobulin); iga, igd, igg, igm, each | N | 1 | $0.00 | ||||||
| 0184 | 2027 | 82787 | Igg 1 2 3 or 4 each | Gammaglobulin (immunoglobulin); immunoglobulin subclasses (eg, igg1, 2, 3, or 4), each | N | 12 | $0.00 | ||||||
| 0185 | 2027 | 82945 | Glucose other fluid | Glucose, body fluid, other than blood | N | 1 | $0.00 | ||||||
| 0186 | 2027 | 83001 | Assay of gonadotropin (fsh) | Gonadotropin; follicle stimulating hormone (fsh) | N | 1 | $0.00 | ||||||
| 0187 | 2027 | 83021 | Hemoglobin chromotography | Hemoglobin fractionation and quantitation; chromatography (eg, a2, s, c, and/or f) | N | 1 | $0.00 | ||||||
| 0188 | 2027 | 83036 | Hemoglobin glycosylated a1c | Hemoglobin; glycosylated (a1c) | N | 32 | $0.00 | ||||||
| 0189 | 2027 | 83050 | Hgb methemoglobin quan | Hemoglobin; methemoglobin, quantitative | N | 16 | $0.00 | ||||||
| 0190 | 2027 | 83516 | Immunoassay nonantibody | Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method | N | 1 | $0.00 | ||||||
| 0191 | 2027 | 83520 | Immunoassay quant nos nonab | Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified | N | 1 | $0.00 | ||||||
| 0192 | 2027 | 83540 | Assay of iron | Iron | N | 1 | $0.00 | ||||||
| 0193 | 2027 | 83735 | Assay of magnesium | Magnesium | N | 20 | $0.00 | ||||||
| 0194 | 2027 | 83930 | Assay of blood osmolality | Osmolality; blood | N | 4 | $0.00 | ||||||
| 0195 | 2027 | 83935 | Assay of urine osmolality | Osmolality; urine | N | 5 | $0.00 | ||||||
| 0196 | 2027 | 83970 | Assay of parathormone | Parathormone (parathyroid hormone) | N | 5 | $0.00 | ||||||
| 0197 | 2027 | 83986 | Assay ph body fluid nos | Ph; body fluid, not otherwise specified | N | 7 | $0.00 | ||||||
| 0198 | 2027 | 84120 | Assay of urine porphyrins | Porphyrins, urine; quantitation and fractionation | N | 4 | $0.00 | ||||||
| 0199 | 2027 | 84132 | Assay of serum potassium | Potassium; serum, plasma or whole blood | N | 5 | $0.00 | ||||||
| 0200 | 2027 | 84145 | Procalcitonin (pct) | Procalcitonin (pct) | N | 3 | $0.00 | ||||||
| 0201 | 2027 | 84153 | Assay of psa total | Prostate specific antigen (psa); total | N | 1 | $0.00 | ||||||
| 0202 | 2027 | 84160 | Assay of protein any source | Protein, total, by refractometry, any source | N | 5 | $0.00 | ||||||
| 0203 | 2027 | 84220 | Assay of pyruvate kinase | Pyruvate kinase | N | 25 | $0.00 | ||||||
| 0204 | 2027 | 84302 | Assay of sweat sodium | Sodium; other source | N | 13 | $0.00 | ||||||
| 0205 | 2027 | 84377 | Sugars multiple qual | Sugars (mono-, di-, and oligosaccharides); multiple qualitative, each specimen | N | 1 | $0.00 | ||||||
| 0206 | 2027 | 84403 | Assay of total testosterone | Testosterone; total | N | 5 | $0.00 | ||||||
| 0207 | 2027 | 84439 | Assay of free thyroxine | Thyroxine; free | N | 3 | $0.00 | ||||||
| 0208 | 2027 | 84443 | Assay thyroid stim hormone | Thyroid stimulating hormone (tsh) | N | 5 | $0.00 | ||||||
| 0209 | 2027 | 84478 | Assay of triglycerides | Triglycerides | N | 1 | $0.00 | ||||||
| 0210 | 2027 | 84481 | Free assay (ft-3) | Triiodothyronine t3; free | N | 3 | $0.00 | ||||||
| 0211 | 2027 | 84484 | Assay of troponin quant | Troponin, quantitative | N | 2 | $0.00 | ||||||
| 0212 | 2027 | 84520 | Assay of urea nitrogen | Urea nitrogen; quantitative | N | 12 | $0.00 | ||||||
| 0213 | 2027 | 84600 | Assay of volatiles | Volatiles (eg, acetic anhydride, diethylether) | N | 5 | $0.00 | ||||||
| 0214 | 2027 | 84703 | Chorionic gonadotropin assay | Gonadotropin, chorionic (hcg); qualitative | N | 1 | $0.00 | ||||||
| 0215 | 2027 | 85014 | Hematocrit | Blood count; hematocrit (hct) | N | 11 | $0.00 | ||||||
| 0216 | 2027 | 85018 | Hemoglobin | Blood count; hemoglobin (hgb) | N | 1 | $0.00 | ||||||
| 0217 | 2027 | 85025 | Complete cbc w/auto diff wbc | Blood count; complete (cbc), automated (hgb, hct, rbc, wbc and platelet count) and automated differential wbc count | N | 6 | $0.00 | ||||||
| 0218 | 2027 | 85027 | Complete cbc automated | Blood count; complete (cbc), automated (hgb, hct, rbc, wbc and platelet count) | N | 1 | $0.00 | ||||||
| 0219 | 2027 | 85045 | Automated reticulocyte count | Blood count; reticulocyte, automated | N | 4 | $0.00 | ||||||
| 0220 | 2027 | 85049 | Automated platelet count | Blood count; platelet, automated | N | 7 | $0.00 | ||||||
| 0221 | 2027 | 85250 | Clot factor ix ptc/chrstmas | Clotting; factor ix (ptc or christmas) | N | 1 | $0.00 | ||||||
| 0222 | 2027 | 85270 | Clot factor xi pta | Clotting; factor xi (pta) | N | 1 | $0.00 | ||||||
| 0223 | 2027 | 85307 | Assay activated protein c | Activated protein c (apc) resistance assay | N | 16 | $0.00 | ||||||
| 0224 | 2027 | 85347 | Coagulation time activated | Coagulation time; activated | N | 12 | $0.00 | ||||||
| 0225 | 2027 | 85384 | Fibrinogen activity | Fibrinogen; activity | N | 13 | $0.00 | ||||||
| 0226 | 2027 | 85390 | Fibrinolysins screen i&r | Fibrinolysins or coagulopathy screen, interpretation and report | N | 12 | $0.00 | ||||||
| 0227 | 2027 | 85460 | Hemoglobin fetal | Hemoglobin or rbcs, fetal, for fetomaternal hemorrhage; differential lysis (kleihauer-betke) | N | 1 | $0.00 | ||||||
| 0228 | 2027 | 85525 | Heparin neutralization | Heparin neutralization | N | 1 | $0.00 | ||||||
| 0229 | 2027 | 85576 | Blood platelet aggregation | Platelet, aggregation (in vitro), each agent | N | 111 | $0.00 | ||||||
| 0230 | 2027 | 85610 | Prothrombin time | Prothrombin time; | N | 9 | $0.00 | ||||||
| 0231 | 2027 | 85611 | Prothrombin test | Prothrombin time; substitution, plasma fractions, each | N | 4 | $0.00 | ||||||
| 0232 | 2027 | 85652 | Rbc sed rate automated | Sedimentation rate, erythrocyte; automated | N | 5 | $0.00 | ||||||
| 0233 | 2027 | 85660 | Rbc sickle cell test | Sickling of rbc, reduction | N | 1 | $0.00 | ||||||
| 0234 | 2027 | 85670 | Thrombin time plasma | Thrombin time; plasma | N | 3 | $0.00 | ||||||
| 0235 | 2027 | 85730 | Thromboplastin time partial | Thromboplastin time, partial (ptt); plasma or whole blood | N | 7 | $0.00 | ||||||
| 0236 | 2027 | 85732 | Thromboplastin time partial | Thromboplastin time, partial (ptt); substitution, plasma fractions, each | N | 2 | $0.00 | ||||||
| 0237 | 2027 | 86022 | Platelet antibodies | Antibody identification; platelet antibodies | N | 12 | $0.00 | ||||||
| 0238 | 2027 | 86038 | Antinuclear antibodies | Antinuclear antibodies (ana); | N | 1 | $0.00 | ||||||
| 0239 | 2027 | 86039 | Antinuclear antibodies (ana) | Antinuclear antibodies (ana); titer | N | 1 | $0.00 | ||||||
| 0240 | 2027 | 86160 | Complement antigen | Complement; antigen, each component | N | 1 | $0.00 | ||||||
| 0241 | 2027 | 86225 | Dna antibody native | Deoxyribonucleic acid (dna) antibody; native or double stranded | N | 1 | $0.00 | ||||||
| 0242 | 2027 | 86235 | Nuclear antigen antibody | Extractable nuclear antigen, antibody to, any method (eg, nrnp, ss-a, ss-b, sm, rnp, sc170, j01), each antibody | N | 1 | $0.00 | ||||||
| 0243 | 2027 | 86317 | Immunoassay infectious agent | Immunoassay for infectious agent antibody, quantitative, not otherwise specified | N | 2 | $0.00 | ||||||
| 0244 | 2027 | 86355 | B cells total count | B cells, total count | N | 1 | $0.00 | ||||||
| 0245 | 2027 | 86359 | T cells total count | T cells; total count | N | 2 | $0.00 | ||||||
| 0246 | 2027 | 86360 | T cell absolute count/ratio | T cells; absolute cd4 and cd8 count, including ratio | N | 1 | $0.00 | ||||||
| 0247 | 2027 | 86376 | Microsomal antibody each | Microsomal antibodies (eg, thyroid or liver-kidney), each | N | 1 | $0.00 | ||||||
| 0248 | 2027 | 86403 | Particle agglut antbdy scrn | Particle agglutination; screen, each antibody | N | 12 | $0.00 | ||||||
| 0249 | 2027 | 86406 | Particle agglut antbdy titr | Particle agglutination; titer, each antibody | N | 3 | $0.00 | ||||||
| 0250 | 2027 | 86635 | Coccidioides antibody | Antibody; coccidioides | N | 1 | $0.00 | ||||||
| 0251 | 2027 | 86641 | Cryptococcus antibody | Antibody; cryptococcus | N | 20 | $0.00 | ||||||
| 0252 | 2027 | 86694 | Herpes simplex nes antbdy | Antibody; herpes simplex, non-specific type test | N | 20 | $0.00 | ||||||
| 0253 | 2027 | 86704 | Hep b core antibody total | Hepatitis b core antibody (hbcab); total | N | 1 | $0.00 | ||||||
| 0254 | 2027 | 86787 | Varicella-zoster antibody | Antibody; varicella-zoster | N | 7 | $0.00 | ||||||
| 0255 | 2027 | 86832 | Hla class i high defin qual | Antibody to human leukocyte antigens (hla), solid phase assays (eg, microspheres or beads, elisa, flow cytometry); high definition qualitative panel for identification of antibody specificities (eg, individual antigen per bead methodology), hla class i | N | 16 | $0.00 | ||||||
| 0256 | 2027 | 86833 | Hla class ii high defin qual | Antibody to human leukocyte antigens (hla), solid phase assays (eg, microspheres or beads, elisa, flow cytometry); high definition qualitative panel for identification of antibody specificities (eg, individual antigen per bead methodology), hla class ii | N | 16 | $0.00 | ||||||
| 0257 | 2027 | 87015 | Specimen infect agnt concntj | Concentration (any type), for infectious agents | N | 11 | $0.00 | ||||||
| 0258 | 2027 | 87070 | Culture othr specimn aerobic | Culture, bacterial; any other source except urine, blood or stool, aerobic, with isolation and presumptive identification of isolates | N | 8 | $0.00 | ||||||
| 0259 | 2027 | 87071 | Culture aerobic quant other | Culture, bacterial; quantitative, aerobic with isolation and presumptive identification of isolates, any source except urine, blood or stool | N | 4 | $0.00 | ||||||
| 0260 | 2027 | 87075 | Cultr bacteria except blood | Culture, bacterial; any source, except blood, anaerobic with isolation and presumptive identification of isolates | N | 9 | $0.00 | ||||||
| 0261 | 2027 | 87077 | Culture aerobic identify | Culture, bacterial; aerobic isolate, additional methods required for definitive identification, each isolate | N | 4 | $0.00 | ||||||
| 0262 | 2027 | 87081 | Culture screen only | Culture, presumptive, pathogenic organisms, screening only; | N | 1 | $0.00 | ||||||
| 0263 | 2027 | 87086 | Urine culture/colony count | Culture, bacterial; quantitative colony count, urine | N | 1 | $0.00 | ||||||
| 0264 | 2027 | 87101 | Skin fungi culture | Culture, fungi (mold or yeast) isolation, with presumptive identification of isolates; skin, hair, or nail | N | 3 | $0.00 | ||||||
| 0265 | 2027 | 87103 | Blood fungus culture | Culture, fungi (mold or yeast) isolation, with presumptive identification of isolates; blood | N | 1 | $0.00 | ||||||
| 0266 | 2027 | 87107 | Fungi identification mold | Culture, fungi, definitive identification, each organism; mold | N | 1 | $0.00 | ||||||
| 0267 | 2027 | 87110 | Chlamydia culture | Culture, chlamydia, any source | N | 1 | $0.00 | ||||||
| 0268 | 2027 | 87116 | Mycobacteria culture | Culture, tubercle or other acid-fast bacilli (eg, tb, afb, mycobacteria) any source, with isolation and presumptive identification of isolates | N | 1 | $0.00 | ||||||
| 0269 | 2027 | 87140 | Culture type immunofluoresc | Culture, typing; immunofluorescent method, each antiserum | N | 2 | $0.00 | ||||||
| 0270 | 2027 | 87143 | Culture typing glc/hplc | Culture, typing; gas liquid chromatography (glc) or high pressure liquid chromatography (hplc) method | N | 1 | $0.00 | ||||||
| 0271 | 2027 | 87147 | Culture type immunologic | Culture, typing; immunologic method, other than immunofluorescence (eg, agglutination grouping), per antiserum | N | 4 | $0.00 | ||||||
| 0272 | 2027 | 87149 | Dna/rna direct probe | Culture, typing; identification by nucleic acid (dna or rna) probe, direct probe technique, per culture or isolate, each organism probed | N | 3 | $0.00 | ||||||
| 0273 | 2027 | 87153 | Dna/rna sequencing | Culture, typing; identification by nucleic acid sequencing method, each isolate (eg, sequencing of the 16s rrna gene) | N | 5 | $0.00 | ||||||
| 0274 | 2027 | 87158 | Culture typing added method | Culture, typing; other methods | N | 20 | $0.00 | ||||||
| 0275 | 2027 | 87169 | Macroscopic exam parasite | Macroscopic examination; parasite | N | 4 | $0.00 | ||||||
| 0276 | 2027 | 87176 | Tissue homogenization cultr | Homogenization, tissue, for culture | N | 12 | $0.00 | ||||||
| 0277 | 2027 | 87177 | Ova and parasites smears | Ova and parasites, direct smears, concentration and identification | N | 5 | $0.00 | ||||||
| 0278 | 2027 | 87181 | Microbe susceptible diffuse | Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip) | N | 1 | $0.00 | ||||||
| 0279 | 2027 | 87184 | Microbe susceptible disk | Susceptibility studies, antimicrobial agent; disk method, per plate (12 or fewer agents) | N | 1 | $0.00 | ||||||
| 0280 | 2027 | 87186 | Microbe susceptible mic | Susceptibility studies, antimicrobial agent; microdilution or agar dilution (minimum inhibitory concentration [mic] or breakpoint), each multi-antimicrobial, per plate | N | 3 | $0.00 | ||||||
| 0281 | 2027 | 87205 | Smear gram stain | Smear, primary source with interpretation; gram or giemsa stain for bacteria, fungi, or cell types | N | 28 | $0.00 | ||||||
| 0282 | 2027 | 87206 | Smear fluorescent/acid stai | Smear, primary source with interpretation; fluorescent and/or acid fast stain for bacteria, fungi, parasites, viruses or cell types | N | 2 | $0.00 | ||||||
| 0283 | 2027 | 87207 | Smear special stain | Smear, primary source with interpretation; special stain for inclusion bodies or parasites (eg, malaria, coccidia, microsporidia, trypanosomes, herpes viruses) | N | 7 | $0.00 | ||||||
| 0284 | 2027 | 87209 | Smear complex stain | Smear, primary source with interpretation; complex special stain (eg, trichrome, iron hemotoxylin) for ova and parasites | N | 4 | $0.00 | ||||||
| 0285 | 2027 | 87210 | Smear wet mount saline/ink | Smear, primary source with interpretation; wet mount for infectious agents (eg, saline, india ink, koh preps) | N | 4 | $0.00 | ||||||
| 0286 | 2027 | 87250 | Virus inoculate eggs/animal | Virus isolation; inoculation of embryonated eggs, or small animal, includes observation and dissection | N | 1 | $0.00 | ||||||
| 0287 | 2027 | 87252 | Virus inoculation tissue | Virus isolation; tissue culture inoculation, observation, and presumptive identification by cytopathic effect | N | 1 | $0.00 | ||||||
| 0288 | 2027 | 87253 | Virus inoculate tissue addl | Virus isolation; tissue culture, additional studies or definitive identification (eg, hemabsorption, neutralization, immunofluorescence stain), each isolate | N | 1 | $0.00 | ||||||
| 0289 | 2027 | 87254 | Virus inoculation shell via | Virus isolation; centrifuge enhanced (shell vial) technique, includes identification with immunofluorescence stain, each virus | N | 1 | $0.00 | ||||||
| 0290 | 2027 | 87255 | Genet virus isolate hsv | Virus isolation; including identification by non-immunologic method, other than by cytopathic effect (eg, virus specific enzymatic activity) | N | 3 | $0.00 | ||||||
| 0291 | 2027 | 87327 | Cryptococcus neoform ag ia | Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; cryptococcus neoformans | N | 13 | $0.00 | ||||||
| 0292 | 2027 | 87328 | Cryptosporidium ag ia | Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; cryptosporidium | N | 11 | $0.00 | ||||||
| 0293 | 2027 | 87329 | Giardia ag ia | Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; giardia | N | 13 | $0.00 | ||||||
| 0294 | 2027 | 87338 | Hpylori stool ag ia | Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; helicobacter pylori, stool | N | 148 | $0.00 | ||||||
| 0295 | 2027 | 87389 | Hiv-1 ag w/hiv-1&-2 ab ag ia | Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; hiv-1 antigen(s), with hiv-1 and hiv-2 antibodies, single result | N | 4 | $0.00 | ||||||
| 0296 | 2027 | 87483 | Cns dna amp probe type 12-25 | Infectious agent detection by nucleic acid (dna or rna); central nervous system pathogen (eg, neisseria meningitidis, streptococcus pneumoniae, listeria, haemophilus influenzae, e. coli, streptococcus agalactiae, enterovirus, human parechovirus, herpes simplex virus type 1 and 2, human herpesvirus 6, cytomegalovirus, varicella zoster virus, cryptococcus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets | N | 15 | $0.00 | ||||||
| 0297 | 2027 | 87486 | Chlmyd pneum dna amp probe | Infectious agent detection by nucleic acid (dna or rna); chlamydia pneumoniae, amplified probe technique | N | 1 | $0.00 | ||||||
| 0298 | 2027 | 87491 | Chlmyd trach dna amp probe | Infectious agent detection by nucleic acid (dna or rna); chlamydia trachomatis, amplified probe technique | N | 11 | $0.00 | ||||||
| 0299 | 2027 | 87496 | Cytomeg dna amp probe | Infectious agent detection by nucleic acid (dna or rna); cytomegalovirus, amplified probe technique | N | 5 | $0.00 | ||||||
| 0300 | 2027 | 87497 | Cytomeg dna quant | Infectious agent detection by nucleic acid (dna or rna); cytomegalovirus, quantification | N | 4 | $0.00 | ||||||
| 0301 | 2027 | 87498 | Enterovirus probe&revrs trns | Infectious agent detection by nucleic acid (dna or rna); enterovirus, amplified probe technique, includes reverse transcription when performed | N | 36 | $0.00 | ||||||
| 0302 | 2027 | 87502 | Influenza dna amp probe | Infectious agent detection by nucleic acid (dna or rna); influenza virus, for multiple types or sub-types, includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, first 2 types or sub-types | N | 7 | $0.00 | ||||||
| 0303 | 2027 | 87503 | Influenza dna amp prob addl | Infectious agent detection by nucleic acid (dna or rna); influenza virus, for multiple types or sub-types, includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, each additional influenza virus type or sub-type beyond 2 (list separately in addition to code for primary procedure) | N | 8 | $0.00 |
This is the start of the file's text. The full file is on GovTribe.
File details come from the government source that posted it. Updated .